Floatz logo

Irinotecan

Refractory Hematologic Malignancy

OHSU Knight Cancer InstituteSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Refractory Hematologic Malignancy cohort.

Asset / SponsorPhaseRating
HUMANIZED, DUAL-AFFINITY RE-TARGETING, OR (DART), MOLECULE THAT RECOGNIZES BOTH CD123 AND CD3
City of Hope Medical Center
Phase 2CCC
Ibrutinib
Curis, Inc.
Phase 1/2CCC
ca-4948
Curis, Inc.
Phase 1/2CCC
DEXAMETHASONE
City of Hope Medical Center
Phase 1CC
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
City of Hope Medical Center
Phase 1CC

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →